Crescendo Biologics
Humabody® has multiple pipeline advantages, including mechanisms to drive broad tumour-killing, increased safety through tumour-specific T-cell activation, and T-cell tumour-specific survival to support a long-lasting anti-cancer effect that avoids systemic toxicity.
Its current lead programme is CB307 — a first-in-class PSMA x CD137 (4-1BB) bispecific molecule with an additional proprietary pipeline of CD137 (4-1BB) bispecifics for the treatment of cancers, targeting MSLN, 5T4 and ROR1.
Crescendo Biologics has global discovery and development collaborators in Takeda and BioNTech and an exclusive, global licensing deal with Zai Lab.
The company’s investors include Andera Partners, BioNTech, IP Group, Quan Capital., Sofinnova Partners, and Takeda. The company was founded around seminal IP generated at the Babraham Institute.
